An impressive annual report has brought the global leader in bioconjugate drug CRDMO, WUXI XDC, into the spotlight. Financial results show that in 2025, the company achieved revenue of RMB 5.94 billion, a year-on-year increase of 46.7%. Gross profit reached RMB 2.14 billion, surging by 72.5%. Adjusted net profit was RMB 1.56 billion, a robust increase of 69.9% year-on-year, and 3.6 percentage points higher than the growth rate in 2024. The profit growth rate significantly outpaced revenue growth, indicating that economies of scale are accelerating.
What has truly captured market attention, however, is the indicator of future prospects: by the end of 2025, the total backlog of unfinished orders soared to $1.49 billion, a substantial increase of 50.3% year-on-year. This implies highly clear revenue visibility for the next 1-2 years, even without considering newly signed projects. During the earnings conference call on March 24th, management stated that the industry continues to grow, and the company's performance momentum remains strong.
WUXI XDC clearly aims to move beyond the label of a "super enabler." Through continuous self-evolution, it is demonstrating the posture of an industry disruptor, having completed several key strategic moves: the controlling acquisition of TOT Biopharm, realizing value release through operational optimization and capacity expansion; a technology licensing collaboration with Earendil Labs for WuXiTecan-2, driving growth in the payload-linker business and creating value from its technology platform; accelerating the capture of opportunities in novel conjugate drugs; and the ongoing expansion of order reserves at its Singapore facility, with CMO business gradually scaling up. Concurrently, the company is further expanding its production capacity footprint through "organic expansion + strategic acquisitions," building a global supply chain system spanning "China + Singapore."
Amid an increasingly crowded ADC/XDC landscape and an external macro environment still fraught with variables, how is this leading player reinforcing its moat? This analysis will delve deeply into the internal logic behind WUXI XDC's high growth and its value anchors.
Part 1: The Strategy Beyond the Financials: Strategic Positioning in the Capacity Cycle and a Value Leap in the Business Model. In early 2026, WUXI XDC announced the controlling acquisition of TOT Biopharm. Given the current ADC capacity shortage, this move was widely interpreted by the market as "capacity expansion." In reality, this is not merely a simple scale increase but a strategic positioning based on the industry cycle. The ADC/XDC field currently faces a structural contradiction: the demand for commercial-scale capacity from late-stage clinical projects is growing exponentially, while the typical cycle for building new capacity is 3-5 years. This could lead to a capacity shortfall in the coming years – orders exist, but capacity does not. For WUXI XDC, using capital to buy time is the most rational choice at this juncture. By acquiring TOT Biopharm's Suzhou facility, the company saves at least 2-3 years of construction time, directly positioning itself for the commercial production ramp-up window in 2026-2027.
Simultaneously, the company unveiled an RMB 8 billion capital expenditure plan for 2026-2030. The confidence for this counter-cyclical expansion in the current financing environment likely rests on two core pillars: First, extremely high order visibility – the $1.49 billion backlog, up 50.3% year-on-year, means capacity for the coming years is largely pre-booked. Second, the strategic positioning of the Singapore facility. Scheduled for GMP release in the first half of 2026, its core purpose is to serve overseas commercial production demand. This is both a capacity layout and a strategic hedge for supply chain diversification. The dual-site model of "China + Singapore" provides clients with a buffer against geopolitical risks.
Beyond strategic moves on the "M" (Manufacturing) front, the continuously evolving innovation technology platform is beginning to build a "second growth curve." Recently, WUXI XDC entered a technology licensing collaboration with Earendil Labs for WuXiTecan-2, with a potential total deal value of up to $885 million. Typically, the traditional CRDMO business model is "service-for-revenue" – charging fees per project, essentially earning service fees. A technology licensing collaboration signifies that the company is entering a phase of value resonance and integration with its clients and their projects. This marks a key strategic move by WUXI XDC within the profit distribution chain of bioconjugate drugs, representing a significant evolution of its business model. The company's moat is no longer comprised solely of execution efficiency and capacity scale but has been elevated to include exclusive intellectual property barriers. When core technology becomes the "infrastructure" for client assets, the CRDMO firm gains leverage in the industry value chain. It is understood that WUXI XDC is actively exploring various models such as technology licensing, collaborative development, and technology transfer to establish a stream of continuous milestone revenues. This is not just a strategic iteration of the revenue structure but a reconstruction of the valuation logic – shifting from linearly growing project revenue to potentially exponential technology royalty income.
Part 2: The Quality Revolution in the Project Funnel: From "Winning Molecules" to "Locking in the Future." Financial reports indicate that WUXI XDC has cumulatively serviced over 1,000 discovery-stage projects, with 252 advancing to the iCMC development stage, and 69 projects successfully converted in 2025. The health of this "funnel" can be analogized as "wide at the top, narrow in the middle, and deep at the bottom." "Wide top" refers to broad front-end intake – 1,000+ discovery projects ensure a continuous influx of new opportunities. "Narrow middle" signifies efficient mid-stage conversion – transitioning from discovery to development requires crossing multiple hurdles like developability; WUXI XDC's technology platform helps clients rapidly validate molecule feasibility, allowing truly promising molecules to advance faster. "Deep bottom" indicates significant back-end accumulation – 18 PPQ projects and 1 commercial manufacturing project signify future contributions from higher-value, scaled revenue.
In the CRDMO industry, the ability to "win molecules" depends on two factors: the appeal of the technology platform and the reputation for project execution. WUXI XDC has compressed the average time from DNA sequence to clinical trial application to 15 months, only half the industry average. This high efficiency is its best competitive edge. The trend of significantly increasing proportions of novel molecules like dual-payload ADCs and bispecific ADCs among the 252 iCMC projects also reflects that innovation in bioconjugates is entering an era of "molecular diversity." ADC is no longer the only form; PDCs, AOCs, and various XDCs are emerging. For WUXI XDC, this means its technology platform must continuously evolve with the industry, possessing "full-category coverage capability." The self-developed "three pillars" – the WuXiDARx™ conjugation technology platform, X-LinC linker technology, and WuXiTecan-1&2 payload-linker technologies – do not constitute isolated technical points but rather a continuously iterating and expanding "technology toolbox." Clients can select different tool combinations based on their needs, and the use of each tool can potentially generate future milestone revenues. This forms the technological foundation for the company's "second growth curve."
Part 3: Reshaping the Industry Niche: How Scale Effects Create a "Positive Feedback Loop." Based on 2025 revenue, WUXI XDC's global market share has exceeded 24%. In the ADC CRDMO track, this signifies that scale effects have formed a self-reinforcing flywheel: more projects lead to more experience, faster technology iteration, stronger client stickiness, and consequently more new projects; larger capacity leads to lower costs, higher cost-effectiveness, greater client attraction, and higher capacity utilization. This "positive feedback loop" is difficult for latecomers to break. Especially in a highly complex field like ADCs, client selection of suppliers is extremely cautious, and once a partnership is established, switching costs are very high. The fact that 14 of the top 20 global pharmaceutical giants by revenue have chosen to collaborate with WUXI XDC is itself the deepest moat, built on trust.
According to the financial report, WUXI XDC's overseas revenue contribution has reached 85%. In the current macro environment, this is both an advantage and a requirement for stronger risk management capability. The advantage lies in serving top global pharmaceutical companies that have the highest standards for technology, quality, and delivery, which forces the company to maintain leading industry delivery standards. The risk lies in the genuine existence of geopolitical uncertainty. WUXI XDC's countermeasure is "global layout + local service," with the establishment of the Singapore facility precisely aimed at building a diversified supply chain system in core markets.
Part 4: The Anchor of Long-Term Value: How a Leader Builds Certainty to Navigate Cycles. Over the past six months, the valuation logic for the biopharmaceutical sector has experienced some fluctuations. Against the backdrop of short-term sentiment versus long-term value, understanding a company's investment anchor has become a market focus. For CDMO companies, judging long-term value can be approached from three dimensions:
First, earnings certainty builds an alpha moat. WUXI XDC's 46.7% revenue growth, 72.5% gross profit increase in 2025, and the 50.3% year-on-year growth of the backlog to $1.49 billion form a solid value foundation. High order visibility means revenue for the next 1-2 years is largely locked in, resulting in very strong earnings predictability.
Second, business model transition brings broad imagination. The realization of technology licensing collaborations signals the company's role beginning to shift from a "water seller" to a "technology stakeholder": using underlying technology to take a stake in client molecules, sharing future post-approval sales royalties. The company's future revenue structure will transition from "linear growth" to a composite model of "linear + optionality." This imaginative potential is not captured by traditional CRDMO valuation frameworks.
Third, capturing the sector's beta红利 (beta红利 - beta红利, meaning beta tailwind or industry growth红利) and riding the momentum. According to Frost & Sullivan projections, the global ADC market size is expected to exceed $115.1 billion by 2032, with a compound annual growth rate of 30.6% from 2023 to 2032. In the ADC/XDC track, arguably the most certain growth story in biopharma for the next decade, WUXI XDC holds a favorable position.
Regarding the company's current state and future direction, WUXI XDC indicates that it is undergoing a transformation from an "industry enabler" to an "industry definer." The essence of this transformation is the concentrated embodiment of its continuous evolution capability. In the long race of bioconjugate drugs, which starts with innovation, succeeds through process, and culminates in capacity, WUXI XDC aims not only to run fast but also to define the rules of the track. Over the next five years, WUXI XDC will strive to achieve a compound annual growth rate of 30%-35% between 2025 and 2030, driving high-quality development through technological innovation depth, project pipeline quality, global capacity layout, and forward-looking strategic investments.
Conclusion Looking back from the vantage point of Q1 2026, WUXI XDC's 2025 performance is far from merely cashing in on cyclical tailwinds; it represents the concentrated爆发 (爆发 -爆发, meaning eruption or culmination) of comprehensive strategic布局 (布局 -布局, meaning layout or planning). From strategic positioning in the capacity cycle to the value leap in its business model, from the quality revolution in its project funnel to the reshaping of its industry niche, this company is demonstrating a clear and powerful growth logic to the market. From multiple perspectives, WUXI XDC has built competitive barriers that are difficult to replicate. Regardless of shifting market winds, focusing on its own fundamentals and letting performance speak remains the best way to address concerns and consolidate trust. What WUXI XDC needs to do is run a little faster and a little steadier on this track.
Comments